Viatris to Acquire Pacira BioSciences for $1.65 Billion

Viatris will acquire Pacira BioSciences in an all-cash transaction valued at $1.65 billion. The pharmaceutical company will pay $36.50 per share for all outstanding common stock to expand its non-opioid pain management portfolio.

The acquisition adds two patent-protected products in the United States: EXPAREL, used for acute postsurgical pain, and ZILRETTA, used for osteoarthritis knee pain. Pacira reported approximately $746 million in total revenue and $177 million in adjusted EBITDA for the twelve months ending June 30, 2026.

Viatris plans to fund the transaction using excess cash and short-term borrowings. The company intends to use its global infrastructure and intellectual property expertise to enter new markets and extend the lifecycles of the acquired products. The deal is expected to be immediately accretive to financial guidance metrics and is anticipated to close by the end of 2026.